Echocardiographic contrast agents: effect of microbubbles and carrier solutions on left ventricular contractility

Functional myocardial perfusion abnormality induced by left ventricular asynchronous contraction: experimental study using myocardial contrast echocardiography

OBJECTIVES

The aim of this study was to clarify how myocardial perfusion is impaired by asynchronous contraction.

BACKGROUND

False septal hypoperfusion is noted in some patients with left bundle branch block.

METHODS

Eight dogs were examined with epicardial pacing at the left ventricular posterior wall, the right ventricular anterior wall and, as a control, the right atrial appendage. The pacing rate was 80, 110 and 150 beats/min (bpm). Myocardial perfusion was assessed by contrast echocardiography.

RESULTS

Left ventricular pacing at 80 and 110 bpm did not change systolic wall thickening or contrast intensity at the pacing site, although an early excitation notch was noted at the pacing site. However, at 150 bpm, systolic thickening was impaired (23.3 +/- 4.2% vs. 37.0 +/- 2.6% during atrial pacing, p < 0.05), and the peak intensity ratio of the pacing site to the ventricular septum was significantly decreased (24.1 +/- 5.7% vs. 37.0 +/- 2.8% at a pacing rate of 80 bpm, p < 0.01). The peak intensity ratio correlated with systolic wall thickening at the pacing site (y = 0.413 x -0.028, r = 0.81, p < 0.0001). However, right ventricular pacing did not change either systolic thickening or the peak intensity ratio at any pacing rate, although an early excitation notch was noted on the ventricular septum.

CONCLUSIONS

Wall motion abnormalities after early excitation vary depending on the pacing mode. When tachycardia induces regional wall motion abnormalities, the ventricular wall of the pacing site is functionally hypoperfused.

Contrast ultrasonography for 2-D opacification of heart cavities, peripheral vessels, kidney and muscle

Contrast ultrasonography of peripheral vessels and peripheral organs has been only sparsely used to evaluate peripheral tissue blood flow. The purpose of the study was to characterize intraluminal opacification of renal and femoral arteries and veins, of skeletal muscle and renal parenchyma after intraarterial (IA) injection of BY963, a newly developed ultrasound contrast agent being evaluated in Phase II and III trials, and to compare it with opacification of heart cavities after intravenous injection (IV) in dogs. A further purpose was to quantitate possible opacification losses during the first transcapillary passage of BY963 through pulmonary and peripheral microcirculation. BY963 was administered at the dose of 5 mL/animal/vascular territory (0.2 mL/kg). The peak intensity (intensity units = IU) and the area-under-the-curve (AUC, IU x heart cycles) were estimated from regions-of-interest placed in the right ventricle (RV), left ventricle (LV), main renal artery and vein, kidney, femoral artery and vein and adductor muscle. Following single IV injection, the average peak intensity and AUC values were 33 +/- 3 (mean +/- SE) and 674 +/- 109 for the RV, and 27 +/- 2 and 870 +/- 74 for the LV (p < 0.05), respectively. Following single IA injection in the descending aorta, the average peak intensities and AUC values were 35 +/- 2 and 613 +/- 139 in the renal artery and 26 +/- 4 (p < 0.05) and 639 +/- 151 in the renal vein (nonsignificant), respectively. For the femoral vessels, the average peak intensities and AUC values were 30 +/- 3 and 469 +/- 63 in the femoral artery, and 21 +/- 2 (p < 0.05) and 517 +/- 44 in the femoral vein (nonsignificant), respectively. The values for the output-to-input intensity ratios for peak intensity and AUC were 0.82 +/- 0.06 and 1.36 +/- 0.12 for the LV/RV ratio, 0.73 +/- 0.08 and 1.02 +/- 0.05 for the renal vein/renal artery ratio, and 0.71 +/- 0.09 and 1.16 +/- 0.13 for the femoral vein/femoral artery ratio, respectively (nonsignificant). In conclusion, these results demonstrate the high opacification potency of BY963 in the LV, renal and femoral veins, being of the same order of magnitude as that in the RV, renal and femoral arteries, respectively. Finally, the loss of opacification properties of BY963 during the first transcapillary (pulmonary or peripheral-capillary) passage is minimal.

Prolonged myocardial contrast echocardiography via peripheral venous administration of QW3600 injection (EchoGen): its efficacy and side effects

We examined the efficacy and side effects of a newly developed contrast agent for intravenous myocardial contrast echocardiography, QW3600 Injection (EchoGen; Sonus Pharmaceuticals, Bothell, Wash.). Doses of 0.1, 0.2, 0.5, and 0.8 ml/kg of this agent were administered intravenously to 8 open-chested dogs. The left ventricular (LV) myocardium was uniformly well opacified for the 0.5 and 0.8 ml/kg doses, for which the peak intensity was an average of 40 gray levels above the baseline intensity. The myocardial opacification persisted even after the contrast echo intensity in the LV cavity had decreased. After ligation of the coronary artery, the area at risk was clearly delineated by the same doses. The agent emulsion and dissolved bubbles were examined microscopically in vitro and in vivo to elucidate the mechanism of prolonged opacification. A microscopic investigation of the mesenteric vessels of a rat indicated that bubbles had formed, growing as large as 30 to 50 microm [corrected] in diameter. The hemodynamic parameters did not change at low doses (0.1 and 0.2 ml/kg), but the systemic pressure fell and the arterial blood oxygen saturation decreased at high doses (0.5 and 0.8 ml/kg). EchoGen provides prolonged contrast for myocardial contrast echocardiography via peripheral venous administration, although the hemodynamic parameters deteriorate at high doses.

Left ventricular papillary muscle perfusion assessed with myocardial contrast echocardiography

This myocardial contrast echocardiographic study shows that left ventricular posteromedial papillary muscle is supplied by either the right or left coronary artery in most subjects, but may be supplied by both coronary arteries. The posteromedial papillary muscle and its adjacent area may be supplied by a different coronary artery.

Echocardiographic contrast agents and left ventricular contractility: evaluation using an isolated rabbit heart model

The effects of Albunex (Molecular Biosystems, Inc., San Diego, Calif.) and a second generation contrast agent, FS069, on left ventricular (LV) contractility were evaluated using an isolated rabbit heart model under constant loading conditions and heart rate. Contrast injections (2 ml total volume) were performed in two separate protocols (N1 = 6, N2 = 6). In protocol 1, various doses of Albunex (0.1 to 2.0 ml in saline solution) were used, and paired control injections of a matched dose of 5% solution of human albumin in saline solution were administered. In protocol 2, LV contractility was assessed during injections of the following solutions: (1) 1:250 suspension of FS069 in saline solution, which caused optimal myocardial contrast enhancement; (2) a 1:25 suspension of FS069; (3) a 1:25 suspension of FS069 prefiltered using an 8 microns pore filter; and (4) 2 ml saline solution as a control. Instantaneous LV pressure was analyzed for variations in peak systolic pressure (peak P) and maximum pressure derivative (peak P'), both indices of LV contractility under conditions of fixed heart rate and chamber volume. Albumin alone caused a transient, dose-dependent depression of LV contractility, reflected by decreases in both peak P and peak P' values. These decreases presumably were caused by the decreasing availability of ionized calcium as a result of calcium binding. No further decrease in contractility was noted when Albunex microspheres were present in the solution. Saline injections caused a transient minor increase in LV contractility, reflected by increases of 4.5% +/- 1.1% and 10.6% +/- 3.8% in peak P and peak P' values, respectively. These levels returned to baseline levels within 2 minutes. A similar response was observed when a 1:250 suspension of FS069 was used. The 1:25 suspension of FS069 caused a bimodal response, with initial rises in peak P and peak P' levels (5.2% +/- 3.6% and 12.8% +/- 6.5%, respectively), followed by minor reductions in contractility (2.0% +/- 2.4% and 1.7% +/- 2.1%, respectively). The latter decrease in contractility caused by the 1:25 suspension of FS069 was eliminated by filtering. The isolated rabbit heart model is a highly sensitive tool that allows accurate and direct assessment of possible adverse effects of intravascular contrast agents on LV contractility. Using this model, we showed that neither Albunex microspheres nor FS069 microspheres impaired myocardial contractility.

Comparison of a new intravenous echo contrast agent (BY 963) with Albunex for opacification of left ventricular cavity

Transpulmonary echo contrast agents improve the evaluation of left ventricular function by two-dimensional echocardiography due to a better endocardial border delineation. To compare the contrast effect in the right and left ventricular cavities, a new transpulmonary echocontrast agent, BY 963 and Albunex were intravenously administered to five non-anaesthetized dogs. The right and left ventricular echocardiographic image intensities were quantitatively measured at 60 cardiac cycles using a commercially available ultrasound system. BY 963 and Albunex were intravenously administered at three doses: 0.01 ml/Kg, 0.05 ml/Kg and 0.1 ml/Kg. The area under the curve (AUC, intensity units x heart cycles) and peak intensity (Peak I, intensity units) were estimated for the right (RV) and left ventricular (LV) cavities at the mid ventricular level using acoustic intensitometry. BY 963 injection produced the following values: At the dose of 0.01, 0.05 and 0.1 ml/Kg the AUC amounted to 702 +/- 449, 877 +/- 470 and 890 +/- 320 intensity units x heart cycles in RV and to 542 +/- 406, 806 +/- 557 and 721 +/- 392 in LV (LV/RV ratios: 77%, 92% and 81%). Peak I was at the doses 0.01, 0.05 and 0.1 ml/Kg 29 +/- 4.7, 33 +/- 5.2 and 35 +/- 3.2 intensity units in RV and 18 +/- 5.9, 21 +/- 6.2 and 20 +/- 3.3 in LV (LV/RV ratios: 62%, 64% and 57%). Albunex also produced right and left heart opacification values: at the doses 0.01, 0.05 and 0.1 ml/Kg the AUC amounted to 416 +/- 231, 493 +/- 231 and 674 +/- 390 in RV and to 71 +/- 71, 158 +/- 102 and 277 +/- 120 in LV (LV/RV ratios: 17%, 34% and 41%). Peak I was at the doses of 0.01, 0.05 and 0.1 ml/Kg 19 +/- 5.2, 23 +/- 5.4 and 29 +/- 4.1 in RV and 8 +/- 4.8, 13 +/- 4.7 and 17 +/- 3.2 in LV (LV/RV ratios: 42%, 57% and 59%). Intravenous injection of BY 963 leads to complete opacification of the left ventricular cavity and to high AUC values and peak intensity values at all three dosages. The loss of contrast effect from the right to the left ventricular cavity was very low: the LV/RV ratio of BY 963 was higher than that of Albunex. The new transpulmonary echo contrast agent BY 963 promises to be an excellent echo contrast agent for the noninvasive assessment of left ventricular function.

Safety and feasibility of renal blood flow determination during kidney transplant surgery with perfusion ultrasonography

Contrast-enhanced perfusion patterns of newly transplanted kidneys were determined in 10 patients. Albumin-stabilized sonicated microspheres were injected into the iliac-renal artery of the transplanted kidney while continuous two-dimensional ultrasound images were recorded. Doppler derived resistance index (RI) of the transplanted kidney's blood flow before injection of contrast (0.68 +/- 0.8) did not differ significantly from RI measured immediately after injection (0.72 +/- 0.13) or RI 24 h after surgery (0.69 +/- 0.11). Heart rate, mean arterial pressure, central venous pressure, and electrocardiogram (ECG) signs for ischemia did not change during contrast injections. Renal scintigraphy and renal biopsy revealed acute tubular necrosis and/or rejection in two patients at 24-48 h. Videodensitometry was used to assess the ratio of inner to outer peak pixel intensity from the recorded tomographic images in six patients. In both patients with acute rejection, the inner to outer cortex peak pixel intensity was greater than 1, whereas it was less than 1 in the remaining four patients with normal postoperative renal function. Visual scores (0-3) of contrast enhancement for three doses of Albunex were evaluated (0.5 mL, 1.0 mL, 2.0 mL). Two milliliters always enabled perfusion assessment. In seven patients the identical dose of Albunex was injected immediately before and 30 s after 2 mg of verapamil was injected directly into the renal artery at the time of surgery. The contrast enhancement score before verapamil (1.4 +/- 0.6) was significantly less than the enhancement score after (2.1 +/- 0.6), implying greater renal blood flow after verapamil.(ABSTRACT TRUNCATED AT 250 WORDS)

Intraoperative perfusion echocardiography

The ability to assess perfusion intraoperatively should enable end-organ evaluation of the effects of therapeutic choices and provide a basis for understanding the mechanisms of disease. Several experimental techniques for assessment of tissue perfusion are being evaluated; contrast echocardiography appears to be adaptable to the perioperative setting because of its portability and relatively modest cost. With further improvements in commercial ultrasound imaging devices and ultrasonic contrast agents, intraoperative contrast echocardiography may prove to be a technique for quantitation of tissue perfusion. Contrast echocardiography is currently being used intraoperatively to assess cardioplegia distribution, coronary bypass graft patency, and coronary artery collateral vessel distribution. In addition, relative change in renal blood flow can be assessed during renal transplant surgery. With continued advancement of ultrasound technology providing linear (or known) acoustic signal response and wider dynamic range for detection of small and large concentrations of contrast agents, tissue blood flow may soon be evaluated with even greater precision.

Reliability of echocardiographic measurements of myocardial perfusion using commercially produced sonicated serum albumin (Albunex)

OBJECTIVES

The purpose of this study was to assess the reproducibility and pitfalls of intracoronary and aortic root sonicated albumin injections, using time-intensity curves, in a large sample of normal dogs.

BACKGROUND

The utility of a new myocardial contrast echocardiographic agent, sonicated serum albumin (Albunex), is currently under investigation. However, the reproducibility, injection techniques and general pitfalls of this contrast agent have not been well characterized.

METHODS

We administered sequential intracoronary and aortic root injections (518 injections) of sonicated albumin in 25 closed chest normal dogs to measure the effectiveness and reproducibility of this product. Time-intensity curves, as a measure of myocardial perfusion, were derived and quantified using an on-line videodensitometric analysis system and two-dimensional echocardiography. Measurements included peak intensity, area under the curve, half-time of descent, alpha-parameter and transit time within a 31- x 31-pixel "region of interest" in the anterior septum. Analyses provided 80% power and a type I error protection of 95%.

RESULTS

The best reproducibility of the variables was half-time of descent for aortic root injections (coefficient of variation [CV] 20%) and peak intensity for intracoronary injections (CV 25%), whereas aortic root area under the curve showed the most variability (CV 41%). Analysis of variance for repeated measures of serial intracoronary and aortic root injections showed no significant systematic variability within subjects for the measured variables. In a comparison between intracoronary and aortic root injection sites, paired t tests showed no significant difference for mean values between these two techniques. There was also no statistically significant difference between manual versus power intracoronary injections. Finally, there was no significant difference among three injection rates (1, 2 and 3 ml/s) in paired intracoronary injections, nor was there a difference among injection rates in paired aortic root injections, except for a lower peak intensity with a 1-ml/s injection rate compared with a 2-ml/s injection rate (p = 0.01). Potential pitfalls include preparation of sonicated albumin, delivery techniques and measurement variables.

CONCLUSIONS

We conclude that the results of serial injections of sonicated albumin show no systemic change or trend in normal dogs. Both intracoronary and aortic root injections at standard injection rates by hand or power injector can be used to quantify time-intensity curves, as measure of myocardial perfusion, with similar variability ranging from 20% to 41%. These results are important in the human model, especially after coronary interventions.

Pitfalls in quantitative contrast echocardiography: the steps to quantitation of perfusion

Current methods used clinically to assess myocardial perfusion are invasive and expensive. As the technology of ultrasound imaging improves, CE may provide a relatively inexpensive, noninvasive means of quantitating myocardial perfusion. Issues regarding stability of microbubble contrast agents must be studied more closely under physiologic conditions. As such, encapsulated microbubbles may provide more stability under physiologic pressures than free gas microbubbles. Introducing high concentrations of contrast, either by hyperconcentrating the contrast agent or by increasing the injection rate, may provide greater stability under physiologic conditions. Further, before quantitative statement of tissue perfusion can be made, the relationship between tracer concentration and system response must be established. Further, a "linear" postprocessing ultrasound setting does not eliminate this requirement as data must still undergo nonlinear transformation during log compression and time-gain compensation. Additionally, issues regarding "electronic thresholding" must be explored more extensively in vivo. Commercial ultrasound scanners, in their present form, may not offer adequate sensitivity for absolute quantitative studies. Further development of modified ultrasound systems may provide sufficient sensitivity for quantitative perfusion imaging. CE offers a potentially powerful tool in the clinical management of patients with ischemic heart disease. Conventional coronary angiography provides information on the size of a lesion, but accompanying tissue perfusion distal to the lesion cannot be determined. Doppler ultrasonography determines velocity of blood flow in large vessels but does not offer the potential to quantitate tissue perfusion. Clearly, CE has a place in the future of diagnostic imaging. The recent work of Ito et al. demonstrated the qualitative potential of CE in the identification of "areas at risk" in patients who had undergone thrombolysis or percutaneous transluminal coronary angioplasty after an acute myocardial infarction. With further improvement in the ultrasound imaging techniques and microbubble stability, CE may offer an inexpensive, noninvasive means of assessing myocardial perfusion.

Safety and efficacy of a new transpulmonary ultrasound contrast agent: initial multicenter clinical results

Myocardial contrast echocardiography has been found to be a safe and useful technique for evaluating relative changes in myocardial perfusion and delineating areas at risk. Although earlier contrast agents required direct delivery into the coronary arteries or aortic root, a new echocardiographic contrast agent, sonicated albumin microspheres (Albunex), has been found to cross the pulmonary circulation in experimental models. To determine the safety and preliminary efficacy of intravenous injections of Albunex in humans, 71 patients at three independent medical institutions underwent two-dimensional echocardiographic examination before, during and after the administration of three intravenous doses of Albunex, ranging from 0.01 to 0.12 ml/kg body weight. All patients provided a complete history and underwent physical and neurologic examination and laboratory and electrocardiographic evaluation before the injections; all evaluations (except for the history) were repeated at 2 h and 3 days after the injections of Albunex. The efficacy of the injections was qualitatively assessed by two independent blinded observers using a grading system of 0 to +3, with 0 indicating an absence of contrast effect and +3 indicating full opacification of the cavities examined. All injections were well tolerated and no serious side effects were noted in any of the patients. Irrespective of dose group, a cavity opacification greater than or equal to +2 was seen in the right ventricle in 212 (88%) of 240 injections and in the left ventricle in 151 (63%) of 240 injections as judged by the independent observers. The degree of ventricular cavity opacification appeared to be dose and concentration related.(ABSTRACT TRUNCATED AT 250 WORDS)

Echocardiographic contrast in two-dimensional echocardiography: new applications for an old technique?

Although Gramiak and Shah first introduced the technique of using contrast enhanced two-dimensional echocardiography in 1968, it has seen a resurgence of new and varied applications. Three of the areas of interest are in the use of microbubble enhanced contrast agents to evaluate: (1) regional myocardial blood flow; (2) regional myocardial function; and (3) myocardial ischemic areas and infarct size. Whether these new approaches will have applications and value in the clinical laboratory is still a matter of conjecture. The objective of this review is to briefly summarize the potential uses and the advantages and disadvantages of each application.

Contrast two-dimensional echocardiography in congenital heart disease: techniques, indications and clinical utility

Saline contrast echocardiography was performed in 889 children from June 1976 through February 1988. One-third of these studies were in postoperative patients. A patent foramen ovale was identified by finding right to left shunting on venous contrast injection in 37% of 127 children studied with a structurally normal heart. The incidence of such shunting was greater at younger ages (55% younger than 1 month versus 22% older than 1 month). In most patients with an atrial or ventricular septal defect, some right to left shunting was demonstrable. The technique was useful in distinguishing different forms of atrial septal defect and identifying muscular ventricular septal defects that were difficult to image directly. The technique was used in the catheterization laboratory to aid in the identification of congenital coronary artery fistulas and was diagnostic in two cases of pulmonary arteriovenous malformation. In patients with situs abnormalities, the technique was useful in identifying the systemic venous connections to the atria. Contrast echocardiography was also used in postoperative evaluations. The technique was useful in identifying patch leaks and residual defects after Senning, Mustard and Fontan operations, and after closure of atrial and ventricular septal defects. Most patients were found to have no superior vena cava obstruction by contrast echocardiography after the Senning or Mustard procedure. Contrast echocardiography continues to be a useful technique in the diagnosis of a wide spectrum of congenital heart disease, as well as in the postoperative evaluation of congenital heart surgery.

Albunex: a safe and effective commercially produced agent for myocardial contrast echocardiography

Microbubble solutions of sonicated human serum albumin have been shown to be effective echocardiographic contrast agents free from adverse effects on coronary blood flow, left ventricular function, and systemic hemodynamics. Albunex is a commercially prepared solution of air-filled albumin microspheres prepared from sonicated 5% human serum albumin. The effects of Albunex on coronary blood flow, left ventricular function, and systemic hemodynamics, as well as contrast enhancement were evaluated in 10 open chest, anesthetized dogs. After an intracoronary injection, Albunex did not alter left atrial, left ventricular systolic or end-diastolic, or mean aortic pressures. It did not cause a coronary hyperemic response, alter left ventricular systolic thickening, or lower the peak positive left ventricular dp/dt. It did not alter these measurements even in the presence of a critical coronary stenosis. The contrast opacification produced by Albunex microbubbles was dose dependent (optimal dose range of 0.033 to 0.5 ml/kg), with attenuation occurring at higher doses. In conclusion, although Albunex provides adequate contrast enhancement, intracoronary injection of Albunex does not significantly alter coronary blood flow, left ventricular function, or systemic hemodynamics. Because of the standardized size and concentration of the microspheres, Albunex may be an ideal agent for myocardial contrast echocardiography.

Myocardial contrast echocardiography without significant hemodynamic effects or reactive hyperemia: a major advantage in the imaging of regional myocardial perfusion

All agents used for myocardial contrast echocardiography to date produce adverse hemodynamic effects and alter coronary blood flow. It was hypothesized that because 5% human albumin, when sonicated for use as a contrast agent, is neither hyperosmolar nor a calcium chelator, it would not have significant effects on coronary blood flow, left ventricular function or systemic hemodynamics. Albumin microbubbles of two distinct sizes (mean size 2.9 and 5.8 micron) were produced and compared with nonsonicated albumin, nonsonicated Renografin, sonicated Renografin and hand-agitated Renografin for their effects on hemodynamics, coronary blood flow and regional left ventricular systolic thickening in 15 open chest anesthetized dogs. None of the albumin solutions significantly altered left atrial, left ventricular systolic and end-diastolic and mean aortic pressures. These agents did not cause a coronary hyperemic response or alter left ventricular systolic thickening, but slightly lowered the peak positive left ventricular maximal rate of rise in pressure (dP/dt) (-4.1 +/- 5.4%, p less than 0.01). In contrast, all the Renografin solutions caused significant changes in all these variables (p less than 0.02). In six dogs. albumin solutions did not alter these variables even in the presence of critical coronary stenosis. The contrast opacification produced by 5.8 micron albumin microbubbles was equivalent to that produced by sonicated Renografin. Compared with an equivalent amount of saline and nonsonicated albumin solutions, 10 ml of sonicated albumin did not produce any evidence of infarction, embolization or hemorrhage in the myocardium, brain or kidneys of rabbits.(ABSTRACT TRUNCATED AT 250 WORDS)

Myocardial contrast two-dimensional echocardiography: dose-myocardial effect relations of intracoronary microbubbles

It is controversial whether echocardiographic contrast agents prepared by sonication cause transient myocardial depression beyond that known to occur with contrast agents alone. In nine open chest dogs, contrast injections were made into the left anterior descending coronary artery during two-dimensional echocardiography. One hundred forty-four recordings were analyzed subsequently, by an observer who was unaware of other data, for percent depression of systolic wall thickening, duration of regional wall motion abnormalities, peak contrast enhancement and contrast washout. Two microbubble sizes were obtained by sonicating Renografin-76 (meglumine sodium diatrizoate): mean diameter 12 +/- 3 (SEE) and 20 +/- 6 micron. Four doses (range 0.5 to 3 ml) of each of four agents (12 and 20 micron bubbles in Renografin, nonsonicated Renografin and saline solution) were injected in random order. Significant relations were found between percent depression of systolic wall thickening, duration of regional wall motion abnormalities and contrast washout time versus microbubble size (p less than 0.001) and microbubble dose (p less than 0.01). Little increased contrast effect was found at larger doses or with larger microbubbles compared with the smaller doses and size studied. Injections of nonsonicated Renografin caused less depression of systolic wall thickening (p less than 0.05), faster resolution of wall motion abnormalities (p less than 0.05), less contrast (p less than 0.001) and more rapid contrast washout (p less than 0.001) than did 12 micron bubbles in Renografin. A significant correlation was found between the duration of regional wall motion abnormalities and contrast washout time (r = 0.93, p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Contrast echocardiography during coronary arteriography in humans: perfusion and anatomic studies

In humans, the physiologic relation between myocardial blood flow and epicardial coronary artery anatomy remains poorly defined. With the recent development of sonicated microbubble contrast agents, it is now possible to use contrast echocardiography to assess myocardial perfusion and to correlate blood flow with angiographically identified coronary artery anatomy. The purpose of the current study was to determine myocardial perfusion patterns in patients without significant coronary artery disease. The results may be used as a reference to analyze myocardial blood flow in patients with coronary artery disease. Sonicated meglumine sodium diatrizoate solution (Renografin-76), which contains microbubbles measuring 4.5 +/- 2.8 micrograms in diameter by laser analysis, was used as the echocardiographic contrast agent during elective coronary arterriography in 14 patients without significant coronary artery disease. Patients received intracoronary injections of 1.5 to 2 ml of sonicated Renografin-76 without complications. Perfusion characteristics were studied by visual assessment of the two-dimensional echocardiographic images obtained after individual injections. In patients found to be free of significant coronary artery disease by arteriography, the left coronary system always supplied the anteroseptal, anterior, anterolateral and posterior regions of the left ventricle at the mid-papillary, cross-sectional level. The right coronary artery system perfused the inferior and inferoseptal regions in 89% of the patients identified with a right dominant system. The anterolateral papillary muscle was perfused from the left coronary system in all cases. The posteromedial papillary muscle was perfused from the left coronary system in 58% of the patients and from the right system in 42% of the patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Effect of intracoronary injections of sonicated microbubbles on left ventricular contractility

Despite the recent interest in contrast-enhanced echocardiography as a means of defining myocardial perfusion, the effects of echo contrast agents on left ventricular (LV) contractility in humans remains poorly defined. This is particularly relevant because intracoronary injection of contrast agents used for angiographic visualization of coronary arteries produces significant alterations in LV hemodynamics. The relation of LV end-systolic wall stress (sigma es) to rate-corrected velocity of fiber shortening (Vcfc), a load-independent index of contractility, was studied in 7 patients undergoing elective coronary arteriography. Two-dimensional and targeted M-mode echocardiographic and central aortic pressure tracings were recorded during injections of standard volumes of angiographic (7 to 9 ml of nonsonicated Renografin-76) and echocardiographic (1.5 to 2.0 ml of sonicated Renografin-76) contrast agents into the left main coronary artery. The order in which agents were injected was randomly determined. Myocardial contractility was assessed under control conditions and 5 and 15 seconds after injection. Alterations in contractility relative to control were measured as the change in Vcfc after elimination of afterload (sigma es) as a confounding variable. An injection of Renografin-76 adequate for angiographic imaging of coronary artery anatomy resulted in a significant depression of LV contractility (p less than 0.001) in conjunction with a tendency toward increased afterload (p = 0.12); recovery occurred by 15 seconds after injection. The smaller amounts of sonicated Renografin-76 required to give adequate contrast enhancement of the myocardium did not alter LV contractile state or afterload.(ABSTRACT TRUNCATED AT 250 WORDS)